greeksoup/ stock research
Stock research / United States / ARQT / Filings

Arcutis Biotherapeutics, Inc. SEC filings

Arcutis Biotherapeutics filed 17 documents with the SEC in the last twelve months, the latest report being the 10-Q of 5 August 2026.

Filings in twelve months177 of them 8-K news
Latest report10-Qfiled 5 Aug 2026
Latest filing10-Q5 Aug 2026
Last results, two-day move+1.5%results filed 5 Aug 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were proxy and other (6). Results came out 3 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 3 releases the share price moved 12.1% on average in the two days around results, the most on 28 Oct 2025 (+28.8%).

28 Oct 2025+28.8%$19.64 to $25.29
25 Feb 2026+5.9%$26.98 to $28.57
5 Aug 2026+1.5%$26.03 to $26.43
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

7 filings

Arcutis Biotherapeutics's 7 news filings (8-K) were mostly about results of operations (3) and officer or director change (3).

  • Results of operationsThe quarterly results release
    3 · latest 5 Aug 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    3 · latest 5 Aug 2026
  • Regulation FD disclosureMaterial shared with investors, often slides or a presentation
    2 · latest 16 Jul 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 9 Jun 2026
  • Other eventsNews the company chose to file
    1 · latest 9 Jun 2026

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months Arcutis Biotherapeutics, Inc. filed 17 documents with the SEC of the kinds listed here: 7 current reports (8-K), about 3 results of operations; 3 officer or director change; 2 regulation FD disclosure; 1 shareholder vote; 1 other events; 3 quarterly reports (10-Q), 2 employee share plan registrations (S-8), 1 annual report to shareholders (ARS), 1 additional proxy material (DEFA14A), 1 proxy statement (DEF 14A), 1 shelf registration (S-3ASR). The latest, filed 5 August 2026: 10-Q, quarterly report. The 10-K, the 10-Qs and the proxy statement themselves, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    5 August 202610-Qquarterly report30 June 2026EDGAR
    5 August 20268-KResults of operations, Officer or director change31 July 2026EDGAR
    16 July 20268-KOfficer or director change, Regulation FD disclosure15 July 2026EDGAR
    9 June 20268-KShareholder vote, Other events5 June 2026EDGAR
    6 May 202610-Qquarterly report31 March 2026EDGAR
    6 May 20268-Kcurrent report6 May 2026EDGAR
    21 April 2026S-8employee share plan registrationEDGAR
    21 April 2026ARSannual report to shareholders21 April 2026EDGAR
    21 April 2026DEFA14Aadditional proxy materialEDGAR
    21 April 2026DEF 14Aproxy statement21 April 2026EDGAR
    25 February 2026S-8employee share plan registrationEDGAR
    25 February 2026S-3ASRshelf registrationEDGAR
    25 February 202610-Kannual report31 December 2025EDGAR
    25 February 20268-KResults of operations25 February 2026EDGAR
    8 December 20258-KOfficer or director change, Regulation FD disclosure3 December 2025EDGAR
    28 October 202510-Qquarterly report30 September 2025EDGAR
    28 October 20258-KResults of operations28 October 2025EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.